Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $7.7152W HIGH $17.68
Volume
3.47 M
Value Traded
59.28 M
Short % Float
17.07%
Days to Cover
6.8
+47.49%Week
+50.04%1 Month
+56.42%3 Month
+73.87%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.44 B
EPS (TTM)
1.04
P/E Ratio
16.69
Ent. Value
2.77 B
Total Shares
141.05 M
Float Shares
21.99 M
Insiders
84.41%
Institutions
15.84%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
ARDT Catalyst Timeline
Dated clinical, regulatory and corporate events for Ardent Health, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Ardent Health, Inc.
1Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Event history 1
Past FDA Catalysts and PDUFA Decisions
How ARDT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Ardent Health, Inc. is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every ARDT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Caspers DaveDirector, Officer (CEO and President) | Grant/Award | 103,653 174,930 held | $0.00 | 07/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ARDT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 0.1 % | 3.52 M | 206.00 K |
Ownership Trends
ARDT Short Interest
Shares sold short, counted twice a month.
17.07%
Short % of Float
of tradable shares sold short
3.8M
Shares Sold Short
-19.0% vs prior count
6.8 High
Days to Cover
trading days of normal volume to buy every short share back
549.3K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ARDT ranks across every disease it competes in
Competitive Position is a premium feature
See how ARDT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialARDT News
-ARDT
Nov 9, 2026▲ +8.8%today
Ardent Health to Participate in the UBS Global Healthcare Conference
Ardent Health will participate in the UBS Global Healthcare Conference on November 10, 2026. The management team will engage in a fireside chat at 11 a.m. ET. Investors can access a live audio webcast of the presentation through the company's Investor Relations section.
Read more →-ARDT
Nov 4, 2026▲ +22.4%on this news· ran to +33% by day 1
Ardent Health Reports Third Quarter 2026 Results
Ardent Health reported strong third quarter results for 2026, with total revenue of $1.62 billion and net income of $45 million. The company experienced a 2.9% year-over-year growth in adjusted admissions and raised its Adjusted EBITDA guidance for the year. Operational efficiencies and strategic capital deployment are expected to enhance margins moving forward.
Read more →-ARDT
Oct 21, 2026Ardent Health Appoints Gaurav Khanna as Chief Digital & Information Officer
Ardent Health appointed Gaurav Khanna as Chief Digital & Information Officer. He will lead the company's technology and digital strategy to enhance patient care and operational efficiency. Khanna has over 20 years of experience in healthcare technology, previously serving at CenterWell Pharmacy and Contessa Health. His expertise aims to support Ardent's growth and strategic goals.
Read more →-ARDT
Oct 15, 2026Ardent Health Announces Third Quarter 2026 Results Conference Call and Webcast Date
Ardent Health has announced the date for its third quarter 2026 results conference call, scheduled for November 5, 2026. The company will release its financial results after market close on November 4, 2026. Investors can participate via a live teleconference or listen to a replay available until November 19, 2026.
Read more →-ARDT
Sep 29, 2026The University of Kansas Health System and Ardent Health Announce Plans to Transition Ownership of St. Francis Campus
The University of Kansas Health System has signed an agreement to acquire full ownership of the St. Francis Campus and its affiliated care locations in Topeka from Ardent Health. This transition follows a nearly decade-long joint venture partnership. The move is expected to streamline operations and improve clinical functions under the new ownership structure.
Read more →-ARDT
Sep 15, 2026Ardent Health Hospitals Earn Recognition in U.S. News & World Report’s 2026-2027 Best Hospitals Rankings
Ardent Health has announced that 13 of its hospitals have been recognized in the U.S. News & World Report's 2026-2027 Best Hospitals rankings. This recognition includes a Best Regional Hospital designation and several regional specialty rankings. Additionally, the hospitals received 34 High Performing ratings across various procedures and conditions, highlighting their commitment to quality healthcare.
Read more →-ARDT
Sep 2, 2026Ardent Health Marks Expansion of Specialty Care in New UT Tyler School of Medicine
Ardent Health has announced the expansion of specialty care services in East Texas through a partnership with the UT Tyler School of Medicine. This initiative marks the establishment of the first integrated hub in the region, combining patient services with physician training. The new facility will enhance healthcare delivery in the area.
Read more →-ARDT
Aug 27, 2026Ardent Health to Participate in the Wells Fargo 21st Annual Healthcare Conference
Ardent Health (NYSE: ARDT) has announced its participation in the Wells Fargo 21st Annual Healthcare Conference scheduled for September 9, 2026, in Boston, Massachusetts. The management team will engage in a fireside chat at 11 a.m. ET. A live audio webcast of the event will be available for interested investors.
Read more →-ARDT
Aug 11, 2026Oklahoma Heart Institute Brings New National Cardiovascular Trials and Technologies to Patients Across the Region
Oklahoma Heart Institute, part of Hillcrest HealthCare System and Ardent Health, is now the sole participant in several national cardiovascular trials in Oklahoma. It recently became the first site in the U.S. to utilize the Supira percutaneous left ventricular assist device as part of the SUPPORT II clinical trial, enhancing patient access to advanced cardiovascular treatments.
Read more →-ARDT
Aug 4, 2026Ardent Health Reports Second Quarter 2026 Results
Ardent Health, a prominent healthcare provider, has released its financial results for the second quarter of 2026, showing positive growth compared to the previous year. The company focuses on serving mid-sized urban communities across the U.S. and has reported an increase in operational metrics. Detailed comparisons and definitions of metrics are provided in the accompanying press release.
Read more →-ARDT
Jul 23, 2026Ardent Health surpasses 1 million patient encounters supported by ambient AI
Ardent Health has achieved a major milestone by surpassing 1 million patient encounters supported by Ambience Healthcare's ambient AI platform. This achievement highlights the organization's commitment to reducing clinician burnout and enhancing the overall provider experience. The technology is utilized in 87% of ambulatory encounters, showcasing its widespread adoption among Ardent-affiliated clinicians.
Read more →-ARDT
Jul 17, 2026Ardent Health Announces Second Quarter 2026 Results Conference Call and Webcast Date
Ardent Health has announced the date for its second quarter 2026 results conference call. The financial results will be released after market close on August 4, 2026, followed by a call on August 5, 2026, at 10 a.m. ET. This event will include a review of the results and a Q&A session.
Read more →-ARDT
Jun 3, 2026▼ -15.5%on this news
Ardent Health to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Ardent Health is set to participate in the Goldman Sachs 47th Annual Global Healthcare Conference. This event is significant for stakeholders in the healthcare sector, providing insights into Ardent Health's strategic direction. Further details about the company's agenda at the conference have not been disclosed.
Read more →-ARDT
Jun 2, 2026Ardent Health Appoints Dave Caspers as CEO
Ardent Health has appointed Dave Caspers as its new CEO. This leadership change is expected to steer the company towards its future goals. Further details regarding Caspers' vision and plans for Ardent Health were not disclosed in the announcement.
Read more →-ARDT
May 14, 2026Ardent Health and Fujifilm Partner to Deliver Synapse Enterprise Imaging Across Radiology and Cardiology Throughout All Facilities
Ardent Health has partnered with Fujifilm to implement Synapse Enterprise Imaging across its radiology and cardiology departments. This collaboration aims to enhance imaging capabilities throughout all Ardent facilities. The initiative is expected to improve patient care and streamline operations, although specific details on implementation and expected outcomes are limited.
Read more →-ARDT
May 5, 2026Ardent Health Reports First Quarter 2026 Results
Ardent Health has reported its financial results for the first quarter of 2026. The article does not provide specific details regarding revenue, expenses, or other financial metrics. It appears to be a preliminary announcement without in-depth analysis or commentary.
Read more →-ARDT
Apr 16, 2026Ardent Health Announces First Quarter 2026 Results Conference Call and Webcast Date
Ardent Health has announced the date for its first quarter 2026 results conference call and webcast. This event will provide insights into the company's financial performance and strategic direction. Details regarding the time and access to the call will be shared in due course.
Read more →-ARDT
Mar 4, 2026Ardent Health Reports Fourth Quarter 2025 Results
Ardent Health, Inc. reported mixed financial results for the fourth quarter of 2025, with total revenue declining by 0.1% year-over-year, amounting to $1.61 billion. While adjusted EBITDA and net income experienced significant decreases compared to the previous year, the company announced a full-year revenue growth of 6.0% and an adjusted EBITDA increase of 9.3%. Operating cash flow saw a notable rise, up 87% from the prior year. Ardent has provided guidance for the upcoming year, projecting total revenue between $6.4 billion and $6.7 billion.
Read more →-ARDT
Nov 18, 2025▲ +5.1%on this news
Ardent Health Announces $50 Million Share Repurchase Program Authorization
Ardent Health (NYSE ARDT) has authorized a $50 million share repurchase program, reflecting confidence in its business strength and commitment to shareholder value. The program aims to enhance financial flexibility while allowing the company to continue pursuing strategic growth, including possible mergers and acquisitions. With a strong cash position of $609 million, Ardent is well-equipped to act on attractive market opportunities.
Read more →-ARDT
Nov 12, 2025Ardent Health Reports Third Quarter 2025 Results
Ardent Health, Inc. reported its financial results for the third quarter of 2025, revealing total revenues of $1.58 billion, which reflects an 8.8% year-over-year growth. However, the company incurred a net loss of $23 million, contrasting with a net income in the same quarter the previous year. Despite these challenges, adjusted EBITDA experienced a notable increase of 46.3%. The financial results were impacted by non-recurring items, including reductions in revenue due to adjustments in accounting estimates and increases in liability reserves.
Read more →About Ardent Health, Inc.
Headquarters340 SEVEN SPRINGS WAY, BRENTWOOD, TN, 37027
BIOPHARMAWATCH ELITE PLUS
Trade the next ARDT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime